Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Event Materials

<< Previous

Bullboard Posts

Next >>

Comment by fatladysings321on Aug 16, 2017 11:02am

123 Views

Post# 26587361

RE:Event Materials

Thanks Sharecropper.

Pvt placement? No wonder they orchestrated a severe drop in the shareprice.

Helluva bargain for participants and too bad for shareholders.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages